Further, two phase 2b trials of lebrikizumab versus placebo in moderate to severe asthma found periostin-high patients (≥50 ng/mL) experienced a 60% reduction in asthma exacerbations and a 9% forced expiratory volume in one second (FEV1) improvement compared to periostin-low patients (<50 ng/mL) [74]. Here, POSTN is linked to asthma.